New antibiotic from MSD

MSD today announced that its new antibiotic has been registered by the Therapeutic Goods Administration for the treatment of common and problematic gram-negative pathogens. The first new antibiotic registered in Australia in almost ten years for the treatment of gram-negative pathogens, ZERBAXA (ceftolozane/tazobactam) is approved for use in hospitals for the treatment of complicated intra-abdominal